Physician profile
Mark A Roberts
NPI 1679659213
$4,013.50
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $1,443 · 2021: $1,064 · 2022: $588 · 2023: $93.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $965.54 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $391.34 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $282.04 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.82 | 2019-2021 | |
| Forte Bio-Pharma LLC | $213.61 | 2020-2022 | |
| Abbvie INC. | $189.48 | 2021-2022 | |
| Esperion Therapeutics, INC. | $187.48 | 2020-2021 | |
| Grifols USA, LLC | $186.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $184.12 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $153.28 | 2019-2020 | |
| Amarin Pharma, INC. | $152.63 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $130.46 | 2019-2020 | |
| Pfizer INC. | $114.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.87 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $84.43 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $56.93 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $49.39 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $48.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $45.73 | 2019-2021 | |
| Amgen INC. | $41.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.80 | 2019-2020 | |
| Shield Therapeutics INC | $24.80 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.58 | 2022 | |
| Vivus LLC | $16.59 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.35 | 2020 | |
| Dexcom, INC. | $14.96 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.43 | 2020 | |
| Eisai INC. | $13.61 | 2021 | |
| Abbott Laboratories | $12.75 | 2021 | |
| Allergan, INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.